Form 4: Randal J. Kirk Increases Stake in Precigen, Inc. with $20 Million Purchase
SEC Form 4 Filing
Randal J. Kirk, a director and 10% owner of Precigen, Inc., acquired 23,529,411 shares of common stock at $0.85 per share on August 9, 2024, increasing his indirect holdings.
Summary
- On August 9, 2024, Randal J. Kirk, a director and 10% owner of Precigen, Inc., purchased 23,529,411 shares of common stock.
- The purchase price was $0.85 per share.
- The shares were acquired indirectly.
- Following the transaction, Mr. Kirk's total indirect beneficial ownership amounts to 64,547,214 shares through various entities including R.J. Kirk Declaration of Trust, Third Security, LLC, and others.
- Mr. Kirk disclaims beneficial ownership of these shares except to the extent of any pecuniary interest.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the significant insider purchase, indicating confidence from a key stakeholder. However, the disclaimer of beneficial ownership tempers the enthusiasm slightly.
Positives
- A director and significant shareholder increasing their investment in the company can be seen as a positive signal.
Management Comments
- Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's prospects. A purchase by a director and significant shareholder like Randal J. Kirk is often viewed positively.
Comparison to Industry Standards
- Comparing this transaction to other insider purchases in the biotechnology sector, the size of the acquisition is substantial, suggesting a strong belief in the company's future prospects.
- Similar transactions in companies like Intellia Therapeutics or CRISPR Therapeutics often lead to increased investor confidence.
Stakeholder Impact
- Shareholders may view this transaction positively, potentially leading to increased investor confidence.
- Employees may see this as a sign of stability and commitment from a key stakeholder.
Key Dates
| Date | Description |
|---|---|
| 08/09/2024 | Date of the transaction where Randal J. Kirk acquired shares of Precigen, Inc. |
| 08/13/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.